



21 July 2015

Dear Optiscan Shareholder

When I assumed the role of Chairman in 2009, the world was in the grips of the Global Financial Crisis. The ramifications of the GFC were far reaching and were particularly relevant to Optiscan having entered the GFC with much R&D ahead of it and therefore with a go forward position that was highly dependent on its ability to attract suitable funding.

During the course of my tenure at Optiscan, I procured more than \$6m in debt and equity to fund R&D into Optiscan's second generation imaging technology, the cornerstone of value creation for Optiscan.

While Optiscan's technology has been in clinical use for nearly 10 years, the past six years has been largely about the development of the second generation imaging platform. The platform produces real time, High Definition, cellular images of a diagnostic quality. This imaging capability will be introduced to the clinical market first through the Company's collaboration with Carl Zeiss and the neurosurgery imaging system to be deployed during brain cancer surgery.

While the initial indications for use of the neuro system will be delineation of tumours during surgery, the calibre of Optiscan's second generation platform has the potential to open a new and vast market of real time in vivo pathology with enormous patient, doctor and health care system benefits.

Beyond neurosurgery there are many potential applications with successful imaging already achieved in ENT, stomach, small bowel, liver, colon, ovaries, cervix, pleura, pancreas, bladder, prostate, and cartilage

Optiscan is now well known to and possess personal relationships with all key corporates in the worldwide microimaging space. Similar exposure now exists with numerous broking and investment houses both locally and abroad. This combined with Optiscan's preeminent standing with Key Opinion Leaders in Australia, the US, Europe and Asia is a powerful platform to leverage success going forward.

The essential building blocks implemented over the past 6 years are now in place and just as Optiscan's time is nigh, now is also the right time to implement high level personnel changes that will deliver a skill set that is best suited to taking this platform through to commercial success.

I am delighted Patrick O'Connor has accepted the role of Chairman of the Board of Optiscan and see this first step as a very positive and natural transition following my 6 years as Chairman. In addition to the appointment of Patrick as Chairman, I am also very pleased that George Cameron Dow has joined the Board as a non-executive director.

I wish Patrick and George all the best in taking Optiscan to the next level.

Yours Faithfully

Angus Holt